Kaushik Patra

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

Bruce E. Sands, Jingjing Chen, Brian G. Feagan et al. · Gastroenterology · 2017 · 277 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

Mark Agius, Gabriela Kłodowska-Duda, Maciej Maciejowski et al. · Multiple Sclerosis Journal · 2017 · 142 citations · Full text

Life Sciences, Immunology, Neurology +17

Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis

Paul Emery, Mark C. Genovese, Ronald van Vollenhoven et al. · The Journal of Rheumatology · 2009 · 98 citations

Medicine, Immunology, Pharmacotherapy +15

Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER

Désirée van der Heijde, Ferdinand C. Breedveld, Arthur Kavanaugh et al. · The Journal of Rheumatology · 2010 · 84 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Elena Schiopu, Soumya Chatterjee, Vivien Hsu et al. · Arthritis Research & Therapy · 2016 · 81 citations · Full text

Life Sciences, Immunology, Pharmacology +17